Annual Drug Patent Expirations for JAKAFI
Jakafi is a drug marketed by Incyte Corp and is included in one NDA. It is available from one supplier. There are eight patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for JAKAFI.
This drug has one hundred and eigthy-four patent family members in forty-five countries.
The generic ingredient in JAKAFI is ruxolitinib phosphate. One supplier is listed for this compound. Additional details are available on the ruxolitinib phosphate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
